This is our standard breast milk fortification in our NICU. One packet (5 mL) of Similac Human Milk Fortifier Concentrated Liquid is added to breast milk feedings when infants reach 100 ml/kg/day. A second packet is added the next day (10 mL total), to make 24 kcal/oz. After infants reach full feedings (160 ml/kg/d), 3 ml/kg of Similac Liquid Protein Fortifier is added (0.5 g/kg protein). This is increased to 6 ml/kg (1 g/kg protein) the next day.

One packet (5 mL) of Similac Human Milk Fortifier Hydrolyzed Protein Concentrated Liquid is added to breast milk feedings when infants reach 100 ml/kg/day. A second packet is added the next day (10 mL total), to make 24 kcal/oz. Feedings then continue to be advanced to full volume (160 ml/kg/d).

Human Milk

Premature Birth of Newborn

Similac Human Milk Fortifier Hydrolyzed Protein Concentrated Liquid

Cardinal Glennon Children's Medical Center

Noninferiority Trial of Liquid Human Milk Fortifier (HMF) Hydrolyzed Protein Versus Liquid HMF With Supplemental Liquid Protein

Extensively Hydrolyzed Liquid Human Milk Fortifier Versus Liquid Human Milk Fortifier With Supplemental Liquid Protein

Weight (grams) at 36 weeks corrected gestational age or time of hospital discharge, whichever is first

Length (cm) at 36 weeks corrected gestational age or time of hospital discharge, whichever is first

Head circumference (cm) at 36 weeks corrected gestational age or time of hospital discharge, whichever is first

Signs of feeding intolerance, including loose stools, emesis, metabolic acidosis, necrotizing enterocolitis. Presence or absence of symptoms.

Bayley Scales of Infant Development III at 18 months of corrected gestational age

Catherine Cibulskis, MD

Assistant Professor of Pediatrics

St. Louis University

infants subjected to corrective surgery for congenital abnormalities and needing prolonged PN using a new generation intravenous lipid emulsion

infants subjected to corrective surgery for congenital abnormalities and needing prolonged PN using a current intravenous lipid emulsion

Intrahepatic, Cholestasis

Exclusive total parenteral nutrition using a new generation intravenous lipid emulsion composed of 30% LCT n-6 (soybean oil), 30% MCT (coconut oil), 25% monounsaturated fatty acids (olive oil), 15% LCT n-3 (fish oil) and α-tocopherol

SMOFlipid

Exclusive total parenteral nutrition using a current intravenous lipid emulsion composed of 50% LCT (soybean oil) and 50% MCT (coconut oil)

Lipofundin

Reduction of Neonatal Parenteral Nutrition Associated Cholestasis Through Lipid Emulsions

Incidence and Severity of Parenteral Nutrition Associated Cholestasis in Neonates Subjected to Major Surgery, Using Two Mixed Intravenous Lipid Emulsions

Conjugated serum bilirubin >1 mg/dl (34 mmol/L) (Moyer, 2004).

The severity of cholestasis was evaluated by the magnitude of the serum conjugated bilirubin and serum γ-glutamyltranspeptidase (GGT).

Luís Pereira-da-Silva

MD, PhD

Centro Hospitalar de Lisboa Central

Chikungunya Virus Infection

Anti-CHIKV immunoglobulins (CHIKVIg) were purified after the Tégéline manufacturing process from a pool of 583 plasma samples from donors in the convalescent phase of CHIKV infections. Anti-CHIKV hyper immune intravenous immunoglobulin (50 mg/ml) is prepared as a powder to be reconstituted. The therapeutic regimen will consist of 2 doses of 0.5 g/kg 12 hours apart.

anti-CHIKV hyperimmune immunoglobulins

Centre Hospitalier de la Basse-Terre

Centre Hospitalier de Cayenne "Andrée ROSEMON"

CHU de Martinique

Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins

Prevention of Chikungunya Infection in Neonates: Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins

The primary endpoint will measure tolerability and safety of anti-CHIKV hyperimmune IVIG. It will be evaluated in all enrolled neonates and will be based on the occurrence of the following events:
patent ductus arteriosus,
ulceronecrotizing enterocolitis,
pulmonary hemorrhage,
tachycardia, hypotension, decreased O2 saturation during anti-CHIKV IVIG infusion,
hemolytic anemia,
fluid overload, as indicated by hyponatremia and/or ascites.

The following secondary endpoints will be evaluated only in neonates born to mothers who had a definite CHIKV-infection.
Neonates will be classified in one of the following 3 categories:
Neonatal CHIKV clinical disease:
Clinical symptoms consistent with acute CHIKV infection
Demonstration of infection based on CHIKV IgM seroconversion and/or identification of CHIKV viremia (positive CHIKV qRT-PCR at Day 3),
Neonatal CHIKV asymptomatic infection:
Absence of any symptom consistent with CHIV infection
Demonstration of infection based on CHIKV IgM seroconversion and/or identification of CHIKV viremia (positive CHIKV qRT-PCR at Day 3),
Neonatal CHIKV infection excluded:
Absence of CHIKV IgM seroconversion.
Below is an indicative list of symptoms that are consistent with Chikungunya infection in neonates:
Skin rash, severe desquamative disorder, bullous dermatitis,
Acral edema
Symptoms of encephalopathy/encephalitis : stupor, seizures, impaired sucking

enterocolitis/phosphatase

Noninferiority Trial of Liquid Human Milk Fortifier (HMF) Hydrolyzed Protein Versus Liquid HMF With Supplemental Liquid Protein

Reduction of Neonatal Parenteral Nutrition Associated Cholestasis Through Lipid Emulsions

Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus